MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study
Open Access
- 23 February 2016
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (14) , 18531-18540
Abstract
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 studyKeywords
This publication has 24 references indexed in Scilit:
- Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 studyThe Lancet Oncology, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentAnnals of Oncology, 2010
- MMP‐2 alters VEGF expression via αVβ3 integrin‐mediated PI3K/AKT signaling in A549 lung cancer cellsInternational Journal of Cancer, 2010
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent GlioblastomaJournal of Clinical Oncology, 2010
- A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic BiomarkersClinical Cancer Research, 2009
- Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast CancerClinical Cancer Research, 2008
- Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBMNeuro-Oncology, 2008
- Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic CellsCancer Cell, 2008
- REporting recommendations for tumour MARKer prognostic studies (REMARK)British Journal of Cancer, 2005